HMGB1 inhibits the IFN-γ–induced PD-L1 expression in NSCLC
- 28 June 2025
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
Abstract
T cells are the most important cytotoxic cells involved in antitumor immune responses. After recognizing the major histocompatibility complex (MHC)–peptide complex, cytokines including interferon-γ (IFN-γ) are released to kill tumor cells. However, IFN-γ can also induce tumor cells to express PD-L1. This molecule can bind to PD-1 on the surface of T cells to exert inhibitory functions. In response to stimuli, like chemoradiotherapy or immunotherapy, tumor cells release damage-associated molecular patterns, including high-mobility group protein B1 (HMGB1). Our previous studies revealed that HMGB1 can increase the antitumor activity of T cells and enhance the secretion of cytokines, including IFN-γ. However, the effect of HMGB1 on PD-L1 expression in non-small cell lung cancer remains unclear. Here, we examined the expression of HMGB1 and PD-L1 in tumor tissue slices of patients with non-small cell lung cancer with high expression of IFN-γ and observed that they exhibited a negative correlation, which was also verified by our analysis in The Cancer Genome Atlas. In vitro experiments demonstrated that HMGB1 could bind to RAGE (receptor for advanced glycation end products) and inhibit IFN-γ induction of PD-L1 by inhibiting the JAK1/STAT3 pathway. In vitro and in vivo experiments indicated that HMGB1 enhanced the antitumor effects of chimeric antigen receptor T cells and inhibited tumor growth. These results showed that HMGB1 inhibited IFN-γ–induced PD-L1 expression, thereby enhancing the antitumor effects of T cells, and confirmed the role of HMGB1 as a prognostic indicator for lung cancer treated with chimeric antigen receptor T cells.Keywords
Funding Information
- National Natural Science Foundation of China (82272873, 81773046, 31900915)
This publication has 51 references indexed in Scilit:
- HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLCCancer Chemotherapy and Pharmacology, 2025
- Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinomaMolecular Immunology, 2021
- HMGB1 as a therapeutic target in diseaseJournal of Cellular Physiology, 2020
- A cycle involving HMGB1, IFN-γ and dendritic cells plays a putative role in anti-tumor immunityCellular Immunology, 2019
- HMGB1 regulates T helper 2 and T helper17 cell differentiation both directly and indirectly in asthmatic miceMolecular Immunology, 2018
- IFN‐γ‐mediated inhibition of lung cancer correlates with PD‐L1 expression and is regulated by PI3K‐AKT signalingInternational Journal of Cancer, 2018
- Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapyCancer Immunology, Immunotherapy, 2017
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunityNature, 2017
- Garcinone D, a natural xanthone promotes C17.2 neural stem cell proliferation: Possible involvement of STAT3/Cyclin D1 pathway and Nrf2/HO-1 pathwayNeuroscience Letters, 2016
- Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathwayImmunobiology, 2012